The stereo-specific effect of D-serine ethylester and the D-cycloserine in ataxic mutant mice.
Spinocerebellar ataxia is one of the most common neurological disorders. However, few therapeutics are effective for the treatment of this disorder. In the present study, we investigated the efficacy of d-serine ethylester and a related substance, d-cycloserine, as therapeutic agents for ataxia in a murine model. Both compounds are known to stereospecific modulate N-methyl-d-aspartate type glutamate receptors, and impaired glutamate-mediated signaling has been implicated in spinocerebellar ataxia. Using a microdialysis method, we found that intraperitoneal administration of d-serine ethylester increases the extracellular content of endogenous d-serine in the mouse cerebellum for at least 3 h. Maximum elevation of the extracellular d-serine was observed at 40 min after injection. An open-field study was used to assay the effect of the d-serine derivatives on movement and ataxia. In mice exhibiting cytosine arabinoside-induced ataxia, d-serine ethylester reduced the falling index in a dose-dependent manner. The effect of d-serine ethylester was stereo-specific in that l-serine ethylester had no effect on the falling index at the maximum doses tested, and was partially inhibited by 5,7-dichlorokynurenate, an antagonist that binds to the glycine-binding site. Locomotor activity was not changed by the d-serine ethylester treatment. d-cycloserine also significantly reduced the falling index of the mice. Both d-serine ethylester and d-cycloserine had longer lasting effects than other potential therapeutic reagents for ataxia. Growing evidence suggests the essential involvement of endogenous d-serine in mammalian brain function, and our results suggest that d-serine derivatives may represent an effective new therapeutic for the treatment of spinocerebellar ataxia.
Saigoh
K
K
Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo, 187-8502, Japan.
Matsui
K
K
Takahashi
K
K
Nishikawa
T
T
Wada
K
K
D000818:Animals; D002531:Cerebellum / Q000187:drug effects / Q000378:metabolism; D003523:Cycloserine / Q000627:therapeutic use*; D003561:Cytarabine; D005110:Extracellular Space; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008818:Mice, Neurologic Mutants; D017551:Microdialysis; D012694:Serine / Q000378:metabolism; D013132:Spinocerebellar Degenerations / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology*; D013237:Stereoisomerism
D003561:Cytarabine; D012694:Serine; D003523:Cycloserine